| pubmed-article:19620483 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0879615 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0939537 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0332197 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0243161 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C1516048 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:19620483 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:19620483 | pubmed:issue | 24 | lld:pubmed |
| pubmed-article:19620483 | pubmed:dateCreated | 2009-8-19 | lld:pubmed |
| pubmed-article:19620483 | pubmed:abstractText | From February 2001 to February 2002, 946 patients with advanced GI stromal tumors (GISTs) treated with imatinib were included in a controlled EORTC/ISG/AGITG (European Organisation for Research and Treatment of Cancer/Italian Sarcoma Group/Australasian Gastro-Intestinal Trials Group) trial. This analysis investigates whether the response classification assessed by RECIST (Response Evaluation Criteria in Solid Tumors), predicts for time to progression (TTP) and overall survival (OS). | lld:pubmed |
| pubmed-article:19620483 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19620483 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19620483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19620483 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19620483 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19620483 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:VerweijJaapJ | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:ReichardtPete... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:SciotRafR | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:LeyvrazSergeS | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:HogendoornPan... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:BuiBinhB | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:BlayJean-Yves... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:JudsonIanI | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:FindlayMichae... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:IsselsRolfR | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:CasaliPaolo... | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:Le CesneAxelA | lld:pubmed |
| pubmed-article:19620483 | pubmed:author | pubmed-author:SchoffskiPatr... | lld:pubmed |
| pubmed-article:19620483 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19620483 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:19620483 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19620483 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19620483 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19620483 | pubmed:pagination | 3969-74 | lld:pubmed |
| pubmed-article:19620483 | pubmed:dateRevised | 2010-9-27 | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:meshHeading | pubmed-meshheading:19620483... | lld:pubmed |
| pubmed-article:19620483 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19620483 | pubmed:articleTitle | Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. | lld:pubmed |
| pubmed-article:19620483 | pubmed:affiliation | Department of Medicine, Institut Gustave Roussy, Villejuif, France. lecesne@igr.fr | lld:pubmed |
| pubmed-article:19620483 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19620483 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19620483 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19620483 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
